VIMOVO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vimovo, and what generic alternatives are available?
Vimovo is a drug marketed by Horizon and is included in one NDA.
The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.
Summary for VIMOVO
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Clinical Trials: | 11 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIMOVO |
Drug Sales Revenues: | Drug sales revenues for VIMOVO |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIMOVO |
What excipients (inactive ingredients) are in VIMOVO? | VIMOVO excipients list |
DailyMed Link: | VIMOVO at DailyMed |
Recent Clinical Trials for VIMOVO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
EMS | Phase 3 |
Hanyang University Seoul Hospital | Phase 2 |
Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 |
Pharmacology for VIMOVO
Anatomical Therapeutic Chemical (ATC) Classes for VIMOVO
Paragraph IV (Patent) Challenges for VIMOVO
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIMOVO | Delayed-release Tablets | esomeprazole magnesium; naproxen | 375 mg/20 mg and 500 mg/20 mg | 022511 | 1 | 2010-11-05 |
US Patents and Regulatory Information for VIMOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIMOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIMOVO
See the table below for patents covering VIMOVO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2100136 | ⤷ Try a Trial | |
Cyprus | 2224 | Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds | ⤷ Try a Trial |
Japan | 3635432 | ⤷ Try a Trial | |
Japan | 3549111 | ⤷ Try a Trial | |
Germany | 707580 | ⤷ Try a Trial | |
European Patent Office | 2260837 | Compositions pharmaceutiques pour l'administration coordonnée d'AINS (Pharmaceutical compositions for the coordinated delivery of NSAIDs) | ⤷ Try a Trial |
Spain | 2236407 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIMOVO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411900 | C01411900/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: POZEN, INC., US |
1411900 | 122012000052 | Germany | ⤷ Try a Trial | PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
0984957 | 430 | Finland | ⤷ Try a Trial | |
1411900 | 2011C/016 | Belgium | ⤷ Try a Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
1411900 | 435 | Finland | ⤷ Try a Trial | |
0984957 | 2012/048 | Ireland | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
0984957 | CR 2012 00035 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |